ArticleChest2018
A Longitudinal Cohort Study of Aspirin Use and Progression of Emphysema-like Lung Characteristics on CT Imaging: The MESA Lung Study.
Article in Chest, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- The Use of Computed Tomography Densitometry for the Assessment of Emphysema in Clinical Trials: A Position Paper from the Fleischner Society.American journal of respiratory and critical care medicine · 2025Pooled it
- Post-COPD: Can Emphysema Be Repaired?American journal of respiratory and critical care medicine · 2025Article
- Platelet activation and COPD-related clinical and imaging characteristics: The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study.Respiratory medicine · 2025Article
- Clinical Outcomes of Aspirin and Clopidogrel among Patients with Chronic Obstructive Lung Disease: Insights from a Meta-Analysis.Journal of clinical medicine · 2024Review
- Inflammation as the nexus: exploring the link between acute myocardial infarction and chronic obstructive pulmonary disease.Frontiers in cardiovascular medicine · 2024Review
- Extrapulmonary Comorbidities Associated with Chronic Obstructive Pulmonary Disease: A Review.International journal of chronic obstructive pulmonary disease · 2024Review
- Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy.Life (Basel, Switzerland) · 2023Review
- Airway and Systemic Prostaglandin E2 Association with COPD Symptoms and Macrophage Phenotype.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2023Article
- Urine and Plasma Markers of Platelet Activation and Respiratory Symptoms in COPD.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2023Article
- Development and Pharmacokinetics of a Novel Acetylsalicylic Acid Dry Powder for Pulmonary Administration.Pharmaceutics · 2022Article
- Glucosamine use, smoking and risk of incident chronic obstructive pulmonary disease: a large prospective cohort study.The British journal of nutrition · 2022Article
- Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong: A cohort study.PLoS medicine · 2022Article
- Observational
- Hypercoagulation in COPD: the clot thickens.ERJ open research · 2021Article
- Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation.Nature reviews. Cardiology · 2021Review
- Nonsteroidal Antiinflammatory Drugs Modify the Effect of Short-Term Air Pollution on Lung Function.American journal of respiratory and critical care medicine · 2020Article
- Impact of Comorbidities and Commonly Used Drugs on Mortality in COPD - Real-World Data from a Primary Care Setting.International journal of chronic obstructive pulmonary disease · 2020Observational
- Role of medical and molecular imaging in COPD.Clinical and translational medicine · 2019Review
- UNSUPERVISED DOMAIN ADAPTION WITH ADVERSARIAL LEARNING (UDAA) FOR EMPHYSEMA SUBTYPING ON CARDIAC CT SCANS: THE MESA STUDY.Proceedings. IEEE International Symposium on Biomedical Imaging · 2019Article
- Observational
Corrections and comments
- Commented on by
Authors and funding
14 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundPlatelet activation reduces pulmonary microvascular blood flow and contributes to inflammation; these factors have been implicated in the pathogenesis of COPD and emphysema. We hypothesized that regular use of aspirin, a platelet inhibitor, would be associated with a slower progression of emphysema-like lung characteristics on CT imaging and a slower decline in lung function.
methodsThe Multi-Ethnic Study of Atherosclerosis (MESA) enrolled participants 45 to 84 years of age without clinical cardiovascular disease from 2000 to 2002. The MESA Lung Study assessed the percentage of emphysema-like lung below -950 Hounsfield units ("percent emphysema") on cardiac (2000-2007) and full-lung CT scans (2010-2012). Regular aspirin use was defined as 3 or more days per week. Mixed-effect models adjusted for demographics, anthropometric features, smoking, hypertension, angiotensin-converting enzyme inhibitor or angiotensin II-receptor blocker use, C-reactive protein levels, sphingomyelin levels, and scanner factors.
resultsAt baseline, the 4,257 participants' mean (± SD) age was 61 ± 10 years, 54% were ever smokers, and 22% used aspirin regularly. On average, percent emphysema increased 0.60 percentage points over 10 years (95% CI, 0.35-0.94). Progression of percent emphysema was slower among regular aspirin users compared with patients who did not use aspirin (fully adjusted model: -0.34% /10 years, 95% CI, -0.60 to -0.08; P = .01). Results were similar in ever smokers and with doses of 81 and 300 to 325 mg and were of greater magnitude among those with airflow limitation. No association was found between aspirin use and change in lung function.
conclusionsRegular aspirin use was associated with a more than 50% reduction in the rate of emphysema progression over 10 years. Further study of aspirin and platelets in emphysema may be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.